NVCR vs. NVRO, PEN, BLCO, TMDX, PRCT, NARI, IRTC, CNMD, ESTA, and PLSE
Should you be buying NovoCure stock or one of its competitors? The main competitors of NovoCure include Nevro (NVRO), Penumbra (PEN), Bausch + Lomb (BLCO), TransMedics Group (TMDX), PROCEPT BioRobotics (PRCT), Inari Medical (NARI), iRhythm Technologies (IRTC), CONMED (CNMD), Establishment Labs (ESTA), and Pulse Biosciences (PLSE). These companies are all part of the "medical" sector.
NovoCure (NASDAQ:NVCR) and Nevro (NYSE:NVRO) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, community ranking, analyst recommendations, institutional ownership and risk.
Nevro received 33 more outperform votes than NovoCure when rated by MarketBeat users. Likewise, 65.49% of users gave Nevro an outperform vote while only 63.60% of users gave NovoCure an outperform vote.
Nevro has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Nevro, indicating that it is currently the more affordable of the two stocks.
In the previous week, NovoCure had 15 more articles in the media than Nevro. MarketBeat recorded 17 mentions for NovoCure and 2 mentions for Nevro. NovoCure's average media sentiment score of 0.53 beat Nevro's score of 0.34 indicating that NovoCure is being referred to more favorably in the media.
84.6% of NovoCure shares are held by institutional investors. Comparatively, 95.5% of Nevro shares are held by institutional investors. 6.3% of NovoCure shares are held by insiders. Comparatively, 3.2% of Nevro shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
NovoCure has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Nevro has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.
NovoCure currently has a consensus price target of $31.88, indicating a potential upside of 67.59%. Nevro has a consensus price target of $17.71, indicating a potential upside of 81.80%. Given Nevro's higher probable upside, analysts clearly believe Nevro is more favorable than NovoCure.
Nevro has a net margin of -19.17% compared to NovoCure's net margin of -36.67%. Nevro's return on equity of -27.48% beat NovoCure's return on equity.
Summary
Nevro beats NovoCure on 10 of the 18 factors compared between the two stocks.
Get NovoCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NovoCure Competitors List
Related Companies and Tools
